Structure Therapeutics
Blai Coll has extensive work experience in the medical and healthcare industry. Blai currently holds the position of VP Endocrine and Metabolism Clinical Development at Structure Therapeutics, starting from May 2022.
Prior to this, Blai worked at Amgen for six years, where they held various roles. Blai served as the Cardiovascular and Metabolic Platform Lead and Medical Affairs at Amgen from June 2020 to May 2022. Before that, they were the US Medical Lead for Repatha from November 2018 to June 2020. Blai also served as the Medical Director for Global Medical Affairs Cardiovascular from September 2017 to November 2018 and as the Clinical Research Medical Director for Amgen Cardiovascular from August 2016 to September 2017.
Blai's earlier work experience includes a position as a Medical Director at AbbVie from January 2013 to July 2016. Prior to that, they worked as an Internal Medicine Fellow at Hospital Sant Joan, Reus from November 2010 to January 2013.
Blai also had experience as the Director of UDETMA, a clinical research organization focused on cardiovascular prevention, from February 2008 to October 2010. Additionally, they served as a Clinical Research Fellow at the Instituto de Salud Carlos III, Hospital Sant Joan, Reus from May 2004 to February 2008. During this time, they received a grant to conduct research in the Atherosclerosis Research Laboratory.
Blai Coll's education history begins in 1991, when they attended the Universitat Autonoma de Barcelona School of Medicine. They pursued a degree in Medicine and completed their studies in 1997, becoming a medical doctor. Blai then went on to specialize in Internal Medicine from 1998 to 2003. Afterward, they pursued a PhD in Medicine at the Universitat Rovira i Virgili from 2004 to 2007. It is also mentioned that Blai has obtained a PhD in Internal Medicine, although specific details regarding the start and end years are not provided.
This person is not in any offices
Structure Therapeutics
Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations inbiologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.